Zytoprotec Appoints Two Board Members
This article was originally published in Scrip
Executive Summary
Biotech company Zytoprotec has appointed Joerg Vienken and Norbert Riedel to its supervisory board. From 1996 to 2013, Vienken was vice president biosciences at Fresenius Medical Care and is a member of the scientific board of the Berlin-Brandenburg Center for regenerative therapies, the Institute of Biocybernetics and Biomedical Engineering of the Polish Academy of Sciences. For more than 10 years Riedel was head of research and development at Baxter and has been involved with or held positions at companies including ARIAD, Naurex (acquired by Allergan), Aptinyx, Jazz Pharmaceuticals and MediGene.
You may also be interested in...
Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Adherence Issues Add Weight To Digital Trials Push
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
Appointments: Five Prime, Depomed, Gilead, Arix Bioscience and Corbus
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.